Stockreport

Results from Mont Blanc Phase 3 Trial of Nicox's NCX 470 in Glaucoma Published in the American Journal of Ophthalmology [Yahoo! Finance]

Bausch + Lomb Corporation  (BLCO) 
PDF First publication of the data from the Mont Blanc Phase 3 trial in a peer-reviewed journal Authors conclude: "NCX 470 could become an important first-line therapy for [Read more]